Amrad Corporation Limited

Cancer research deal signed for development of VEGF-B

Published in Pharma Law Weekly, November 30th, 2004

Amrad Corporation Limited (AML) and the Ludwig Institute for Cancer Research (LICR) announced a strengthening of their collaboration for the development of Vascular Endothelial Growth Factor B (VEGF-B) and associated intellectual property, which has potential applications in the treatment of cancer and cardiovascular disease.

VEGF-B is one of a family of molecules naturally produced by the body to regulate the growth of new blood vessels, a process called angiogenesis. VEGF-B has been shown in animal models to promote the growth of blood vessels in the heart and this activity may have applications in cardiovascular disease.

Conversely, inappropriate...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2004-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry